- Aligos Therapeutics Inc (NASDAQ:ALGS) has priced a previously announced underwritten public offering of 4.4 million shares at $19 per share, representing a discount of 7% from the last close price of $20.3 on Wednesday.
- The gross proceeds will be approximately $83.6 million.
- Underwriters have an option to purchase up to an additional 660,000 shares.
- The offering will close by July 6.
- J.P. Morgan, Jefferies, and Piper Sandler are acting as the joint book-running managers for the offering. Cantor is acting as a lead manager for the offering.
- Recently, the company announced preliminary data in healthy volunteers from Phase 1a/b multi-part trial of Aligos’ S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) compound ALG-010133.
- Price Action: ALGS shares closed at $20.3 on Wednesday.
Morgan Stanley Maintains Equal-Weight on TE Connectivity, Raises Price Target to $162
Morgan Stanley maintains TE Connectivity (NYSE:TEL) with a Equal-Weight and raises the price target from $149 to $162.
